Association of risk factors and bleeding complications in Asian patients taking edoxaban

Br J Clin Pharmacol. 2021 Apr;87(4):2121-2127. doi: 10.1111/bcp.14623. Epub 2020 Nov 15.

Abstract

Aims: Asian patients are known to be more prone to bleeding complications than patients of other ethnicities. Therefore, there are possibilities of other risk factors that should be given special consideration for dosage adjustment in this specific ethnic group. This study aimed to investigate the risk factors for bleeding complications in Asian patients under appropriate edoxaban dosage regimens.

Methods: Data on patients taking proper dosages, based on the Lixiana package insert, were analysed. Univariate and multivariable analyses were conducted to evaluate associations between risk factors and bleeding outcomes. Subgroup analysis was performed on high-risk patients for bleeding complications whose edoxaban dose was reduced according to the package insert.

Results: In total, 346 patients were included. Among them, 32 patients experienced bleeding complications. Patients with weight ≤60 kg and with cancer showed around 3.3- and 3.4-fold increased risk of bleeding complications compared to heavier patients (>60 kg) and those without cancer, respectively. In subgroup analysis with high-risk patients who took low-dose edoxaban (15 and 30 mg), weight ≤60 kg remained a significant factor for bleeding outcomes.

Conclusion: This study showed that weight ≤60 kg and the presence of cancers could affect bleeding complications, which occurred despite proper edoxaban treatment in Asian patients. Therefore, more strict dosage guideline could be considered in populations with high proportions of Asian ethnicities.

Keywords: anticoagulant; bleeding; edoxaban.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants
  • Atrial Fibrillation*
  • Factor Xa Inhibitors* / adverse effects
  • Humans
  • Pyridines
  • Risk Factors
  • Thiazoles / adverse effects
  • Treatment Outcome

Substances

  • Anticoagulants
  • Factor Xa Inhibitors
  • Pyridines
  • Thiazoles
  • edoxaban